Literature DB >> 27308732

Endometrial cancer: Not your grandmother's cancer.

Jessica N McAlpine1, Sarah M Temkin2, Helen J Mackay3.   

Abstract

Worldwide, the incidence of endometrial carcinoma (EC) is rapidly increasing, and the highest disease burden is reported in North America and Western Europe. Although the prognosis remains good for patients with are diagnosed with early stage EC, for those with recurrent or metastatic disease, the options are few, and the median overall survival is short. It is imperative to gain a greater understanding of all aspects of EC, limit its effect on scarce health care resources and, more importantly, prevent this cancer from significantly impacting future generations of women. An exciting new era of endometrial cancer research and clinical management has begun that incorporates biologically and clinically relevant genomic and clinicopathologic parameters. Continued collaborative research efforts and funding are essential if we are to advance our understanding of this disease and improve clinical outcomes. Cancer 2016.
© 2016 American Cancer Society. Cancer 2016;122:2787-2798. © 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  DNA polymerase ε catalytic subunit (POLE) mutations; Lynch syndrome; The Cancer Genome Atlas (TCGA); clinical trials; endometrial cancer; genomics; molecular classification; obesity and lifestyle factors; targeted therapy

Mesh:

Year:  2016        PMID: 27308732     DOI: 10.1002/cncr.30094

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  48 in total

1.  Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.

Authors:  He Zhu; Yue-Mei Jin; Xue-Man Lyu; Li-Mei Fan; Fei Wu
Journal:  Cell Cycle       Date:  2019-08-14       Impact factor: 4.534

2.  Pterostilbene suppresses human endometrial cancer cells in vitro by down-regulating miR-663b.

Authors:  Ya-Ling Wang; Yuan Shen; Jian-Ping Xu; Kun Han; Yan Zhou; Su Yang; Jun-Yi Yin; Da-Liu Min; Hai-Yan Hu
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

3.  ZEB1 promotes invasion and metastasis of endometrial cancer by interacting with HDGF and inducing its transcription.

Authors:  Yan-Yi Xiao; Li Lin; Yong-Hao Li; Hui-Ping Jiang; Li-Tong Zhu; Yuan-Run Deng; Dan Lin; Wei Chen; Cheng-Ying Zeng; Li-Jing Wang; Shao-Cheng Chen; Qing-Ping Jiang; Chun-Hua Liu; Wei-Yi Fang; Sui-Qun Guo
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

4.  The clinical significance of DJ-1 and HE4 in patients with endometrial cancer.

Authors:  Marco Benati; Martina Montagnana; Elisa Danese; Elisa Paviati; Silvia Giudici; Orazio Ruzzenente; Massimo Franchi; Giuseppe Lippi
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

Review 5.  Melatonin and its mechanism of action in the female reproductive system and related malignancies.

Authors:  Maryam Ezzati; Kobra Velaei; Raziyeh Kheirjou
Journal:  Mol Cell Biochem       Date:  2021-04-17       Impact factor: 3.396

6.  Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.

Authors:  Marisa R Moroney; Kurtis D Davies; Adam C Wilberger; Jeanelle Sheeder; Miriam D Post; Amber A Berning; Christine Fisher; Carolyn Lefkowits; Saketh R Guntupalli; Kian Behbakht; Bradley R Corr
Journal:  Gynecol Oncol       Date:  2019-03-22       Impact factor: 5.482

7.  Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.

Authors:  Kumaravel Mohankumar; Xi Li; Subhashree Sridharan; Keshav Karki; Stephen Safe
Journal:  Gynecol Oncol       Date:  2019-04-30       Impact factor: 5.482

8.  Grade 1 Endometrioid Carcinoma With an Area of Serous Carcinoma Less than 5% Is More Aggressive than Stage IA Pure-type Grade 1 Endometrioid Carcinoma.

Authors:  Morikazu Miyamoto; Hitoshi Tsuda; Atsushi Sugiura; Tsunekazu Kita; Yoshitaka Kataoka; Kenji Ishii; Kazuya Kudo; Hiroko Matsuura; Hiroki Ishibashi; Hideki Iwahashi; Taira Hada; Rie Suzuki; Masashi Takano
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

9.  Protopanaxadiol and metformin synergistically inhibit estrogen-mediated proliferation and anti-autophagy effects in endometrial cancer cells.

Authors:  Chun-Jie Gu; Jiao Cheng; Bing Zhang; Shao-Liang Yang; Feng Xie; Jian-Song Sun; Li-Qing Huang; Jin-Jin Yu; Ming-Qing Li
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

10.  MicroRNA-20a-5p inhibits epithelial to mesenchymal transition and invasion of endometrial cancer cells by targeting STAT3.

Authors:  Yu Huang; Nian Yang
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.